This clinical trial (LASN01-CL-001) consists of 3 parts, each part containing adaptive design elements that can be modified.~Part A will comprise a single-dose administration in healthy participants in 5 dose cohorts of 8 participants each. Part B will comprise a multiple-dose administration in healthy participants in 2 dose cohorts of 8 participants each. Part C will comprise a multiple-dose administration in a single cohort of approximately 8 to 12 participants.~In each part of the study, participants will be randomized to receive IV doses of LASN01 or placebo.
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for fibrosis and oncology. This study is a three-part trial consisting of Parts A, B and C.~The primary objective of this study is to evaluate the safety, tolerability, and the secondary objective is to evaluate the immunogenicity and pharmacokinetics of single and multiple doses of LASN01 in healthy participants, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD).